Demant A/S, a hearing healthcare company, develops, manufactures, and sells products and equipment to enhance people’s hearing in Europe, North America, the Pacific, Asia, and internationally. More Details
Reasonable growth potential with mediocre balance sheet.
Share Price & News
How has Demant's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: WILL.F has not had significant price volatility in the past 3 months.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: WILL.F underperformed the US Medical Equipment industry which returned 14% over the past year.
Return vs Market: WILL.F underperformed the US Market which returned 12% over the past year.
Price Volatility Vs. Market
How volatile is Demant's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Demant undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: WILL.F ($29.26) is trading above our estimate of fair value ($25.5)
Significantly Below Fair Value: WILL.F is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: WILL.F is poor value based on its PE Ratio (53.1x) compared to the US Medical Equipment industry average (47.2x).
PE vs Market: WILL.F is poor value based on its PE Ratio (53.1x) compared to the US market (17.5x).
Price to Earnings Growth Ratio
PEG Ratio: WILL.F is poor value based on its PEG Ratio (1.9x)
Price to Book Ratio
PB vs Industry: WILL.F is overvalued based on its PB Ratio (5.8x) compared to the US Medical Equipment industry average (3.7x).
How is Demant forecast to perform in the next 1 to 3 years based on estimates from 20 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: WILL.F's forecast earnings growth (28.6% per year) is above the savings rate (2.2%).
Earnings vs Market: WILL.F's earnings (28.6% per year) are forecast to grow faster than the US market (22.9% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: WILL.F's revenue (10.4% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: WILL.F's revenue (10.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: WILL.F's Return on Equity is forecast to be low in 3 years time (20%).
How has Demant performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: WILL.F has high quality earnings.
Growing Profit Margin: WILL.F's current net profit margins (6%) are lower than last year (11.7%).
Past Earnings Growth Analysis
Earnings Trend: WILL.F's earnings have declined by 0.06% per year over the past 5 years.
Accelerating Growth: WILL.F's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: WILL.F had negative earnings growth (-51.7%) over the past year, making it difficult to compare to the Medical Equipment industry average (1.8%).
Return on Equity
High ROE: WILL.F's Return on Equity (11%) is considered low.
How is Demant's financial position?
Financial Position Analysis
Short Term Liabilities: WILL.F's short term assets (DKK6.4B) do not cover its short term liabilities (DKK9.5B).
Long Term Liabilities: WILL.F's short term assets (DKK6.4B) exceed its long term liabilities (DKK5.1B).
Debt to Equity History and Analysis
Debt Level: WILL.F's debt to equity ratio (112.6%) is considered high.
Reducing Debt: WILL.F's debt to equity ratio has increased from 60% to 112.6% over the past 5 years.
Debt Coverage: WILL.F's debt is well covered by operating cash flow (21.8%).
Interest Coverage: WILL.F's interest payments on its debt are well covered by EBIT (7.1x coverage).
What is Demant current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate WILL.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate WILL.F's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if WILL.F's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if WILL.F's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of WILL.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Søren Nielsen (50 yo)
Mr. Søren Nielsen has been the Chief Executive Officer and President of Demant A/S (formerly known as William Demant Holding A/S) since April 1, 2017 and has been its Member of Executive Board since Septem ...
CEO Compensation Analysis
Compensation vs Market: Søren's total compensation ($USD2.32M) is below average for companies of similar size in the US market ($USD7.46M).
Compensation vs Earnings: Søren's compensation has been consistent with company performance over the past year.
|CEO, President & Member of Executive Board||3.42yrs||kr.14.70m||0.0077% |
|CFO & Member of Executive Board||5yrs||kr.6.50m||0.0050% |
|Director of Investor Relations||0.50yr||no data||no data|
|Vice President of Corporate Communication & Relations||no data||no data||no data|
|President of Oticon Medical||no data||no data||no data|
|Investor Relations Officer||no data||no data||no data|
Experienced Management: WILL.F's management team is considered experienced (3.4 years average tenure).
|Deputy Chairman||3.42yrs||no data||0.42% |
|Independent Chairman||3.67yrs||no data||0.0034% |
|Independent Director||4.67yrs||no data||0.0094% |
|Director||3.58yrs||no data||0.00015% |
|Independent Director||6.67yrs||no data||0.0013% |
|Director||5.67yrs||no data||0.00056% |
|Director||1.67yrs||no data||0.00021% |
|Director||0.50yr||no data||no data|
Experienced Board: WILL.F's board of directors are considered experienced (3.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Demant A/S's company bio, employee growth, exchange listings and data sources
- Name: Demant A/S
- Ticker: WILL.F
- Exchange: OTCPK
- Founded: 1904
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: kr.43.128b
- Listing Market Cap: kr.6.804b
- Shares outstanding: 239.67m
- Website: https://www.demant.com
Number of Employees
- Demant A/S
- Kongebakken 9
- Capital Region of Denmark
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|WILL.F||OTCPK (Pink Sheets LLC)||Yes||Share Capital||US||USD||May 1995|
|DEMANT||CPSE (OMX Nordic Exchange Copenhagen)||Yes||Share Capital||DK||DKK||May 1995|
|WDH1||DB (Deutsche Boerse AG)||Yes||Share Capital||DE||EUR||May 1995|
|0RGT||LSE (London Stock Exchange)||Yes||Share Capital||GB||DKK||May 1995|
|DEMANC||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Share Capital||GB||DKK||May 1995|
|DEMA||WBAG (Wiener Boerse AG)||Yes||Share Capital||AT||EUR||May 1995|
|WILY.Y||OTCPK (Pink Sheets LLC)||UNSPONSORED ADS||US||USD||Nov 2008|
Demant A/S, a hearing healthcare company, develops, manufactures, and sells products and equipment to enhance people’s hearing in Europe, North America, the Pacific, Asia, and internationally. Its products ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/09/26 06:08|
|End of Day Share Price||2020/09/23 00:00|